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Seoul, Republic of KoreaAbstractBecause there are no available molecular markers for pulmonary mucormycosis (PM), which has low culture sensitivity, early diagnosis and
treatment rely heavily on imaging modes such as computed tomography (CT). However, there are limited data comparing CT ﬁndings for PM
with those for invasive pulmonary aspergillosis (IPA). Adult patients who met the modiﬁed criteria for proven and probable PM (over an 11-
year period) and IPA (over a 6-year period, owing to the availability of the galactomannan assay) according to the modiﬁed European
Organization for Research and Treatment of Cancer/Mycosis Study Group deﬁnitions were retrospectively enrolled. IPA cases were
selected at a 1 : 4 (PM/IPA) ratio. Thoracic CT scans were reviewed by two experienced radiologists blinded to the patients’
demographics and clinical outcomes. A total of 24 patients with PM, including 20 (83%) with proven PM and four (17%) with probable
PM, and 96 patients with IPA, including 12 (13%) with proven IPA and 84 (87%) with probable IPA, were eventually analysed. The
reverse halo sign was more common in patients with PM (54%) than in those with IPA (6%, p < 0.001), whereas some airway-invasive
features, such as clusters of centrilobular nodules, peribronchial consolidations, and bronchial wall thickening, were more common in
patients with IPA (IPA 52% vs. PM 29%, p 0.04; IPA 49% vs. PM 21%, p 0.01; IPA 34% vs. PM 4%, p 0.003, respectively). The reverse
halo sign was more common, and airway-invasive features were less common, in patients with PM than in those with IPA. These ﬁndings
may help physicians to initiate Zygomycetes-active antifungal treatment earlier.
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J. Jung and M. Y. Kim contributed equally to this study.IntroductionRecently, chest computed tomography (CT) has given us
important clues for the clinical suspicion and early treatment of
invasive mould pneumonia in immunocompromised patients
[1,2]. The CT ﬁndings of invasive pulmonary aspergillosis (IPA)Microbiol Infect 2015; 21: 684.e11–684.e18
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.03.019in immunocompromised patients have been relatively well
described [3,4]. However, there are limited data comparing CT
ﬁndings for pulmonary mucormycosis (PM) with those for IPA.
To our knowledge, there has been only one report comparing
clinical and radiological ﬁndings in PM and IPA [5], and it
demonstrated that multiple (ten or more nodules) and pleural
effusion were independent predictors of PM [5]. A recent study
reported that the reverse halo sign (RHS) was present in 15
(94%) of 16 patients with PM during the ﬁrst week of the dis-
ease, and the authors proposed that the RHS could be a sen-
sitive sign for PM, especially early in the disease [6]. However,
whether the RHS is speciﬁc for PM can only be discovered by
comparing the radiological ﬁndings for IPA with those for PM.
We therefore compared the ﬁndings for PM and for IPA.ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Jung et al. Comparison of CT ﬁndings between PM and IPA 684.e12Materials and methodsStudy population
This study was performed at the Asan Medical Centre, a 2700-
bed tertiary-care teaching hospital in Seoul, South Korea. The
medical records of adult patients (aged 16 years) who met the
criteria for proven or probable PM were retrospectively
reviewed from January 2003 to December 2013. In addition, all
patients who met the criteria for proven or probable IPA from
January 2008 to December 2013 were retrospectively
reviewed. Because the galactomannan (GM) assay became
available in our hospital in 2008, IPA cases between January
2008 and December 2013 were enrolled. We excluded patients
with PM or IPA and co-infection with other pathogens.
Deﬁnitions
Proven PM was deﬁned by histological evidence of tissue
invasion consisting of non-septated, right-angle branching
ﬁlamentous fungi plus recovery of Mucorale species by culture
of specimens from pulmonary tissue or positivity for immu-
nohistochemical staining with anti-Rhizopus arrhizus mono-
clonal antibody (LSBio, Seattle, WA, USA). Probable PM was
deﬁned as the presence of host factors together with one or
more clinical indications, such as dense, well-circumscribed
lesions with or without a halo sign, and an air-crescent
sign or cavity on CT, and mycological evidence of Zygomy-
cetes in sputum or bronchoalveolar lavage (BAL) ﬂuid culture,
as deﬁned by the revised criteria of the European Organi-
zation for Research and Treatment of Cancer/Mycosis Study
Group [7].
Proven IPA was deﬁned by histological evidence of tissue
invasion consisting of septated, acutely branching ﬁlamentous
fungi plus recovery of Aspergillus species by culture of pul-
monary tissue, or positivity for immunohistochemical staining
with anti-Aspergillus monoclonal antibody (LSBio). Probable
IPA was deﬁned as the presence of host factors together with
one or more clinical indications such as dense, well-
circumscribed lesions with or without a halo sign, and an
air-crescent sign or cavity on CT, and mycological evidence of
fungal infection (by culture or cytological analysis of BAL ﬂuid
for Aspergillus species, or GM assay of serum or BAL ﬂuid) as,
deﬁned by the revised criteria of the European Organization
for Research and Treatment of Cancer/Mycosis Study Group
[7,8].
IPA cases were selected in a 4 : 1 ratio to PM cases. The
selection was performed in the following order (diagnostic
certainty order) to achieve the calculated sample size: (a) all
patients with proven IPA; (b) all patients with probable IPA
whose sputa or BAL ﬂuids yielded Aspergillus species; and (c)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inferandomly selected patients with probable IPA, with negative
culture of sputa or BAL ﬂuid.
CT evaluation
CT evaluation was performed by two radiologists who were
unaware of patients’ characteristics and clinical outcomes. The
ﬁnal decision was made by consensus after discussion.
We used a glossary of CT imaging deﬁnitions to categorize
pulmonary lesions [9]. Radiological patterns of IPA were clas-
siﬁed, on the basis of previous studies, as: (a) angio-invasive
pneumonia, (b) airway-invasive pneumonia, and (c) necrotizing
pneumonia [10,11]. The following radiological patterns were
considered to be angio-invasive: macronodules (Figs S1A and
S4D), mass-shaped consolidations (Fig S4A–C), infarct-shaped
onsolidations (Fig S1A–C), or halo signs (Fig S4A,B). The
following radiological patterns were considered to be airway
invasive: clusters of centrilobular nodules (Fig S2A–D), peri-
bronchial consolidations (Fig S2A–D), ground-glass opacities
(Fig S2D), and smooth bronchial wall thickening (Fig S2A–C).
The following radiological patterns were considered to indicate
necrotizing pneumonia: air-crescent signs (not shown), cavitary
lesions (Figs S1C and S2B), internal low attenuation as
compared with muscle (Fig S3A,B), the RHS (Fig S4A–C) or the
bird’s nest sign (BNS) (Fig S3B,C).
A typical RHS (Fig S4A–C) was deﬁned as a mass-like lesion
with a central ground-glass opacity or central lucency, or sur-
rounded by a ring of consolidation, regardless of size [12]. A
BNS (Fig S3B,C) was deﬁned as a mass-like lesion, intermingled
with central necrotic low attenuation, small cavities, and
ground-glass opacities surrounded by a ring of consolidations
>3 cm in long diameter [13]. The RHS and BNS have been used
without distinction in previous studies [6,13]. We used RHS as
a combined term for typical RHS (with a more organized
pneumonia-like appearance) and BNS (with a more necrosis-
like appearance), because RHS is the preferred term accord-
ing to the Fleischner Society [9].
We investigated and compared the evolution of thoracic CT
ﬁndings in PM and IPA according to stage, with the stage divided
into three periods (days 0–5, days 6–14, and day 15 onwards).
Day 0 of the disease was deﬁned as the day of the ﬁrst clinical
symptoms and signs.
Statistical analysis
Categorical variables were compared by use of the χ2-test or
Fisher’s exact test, as appropriate, and continuous variables
were compared by the use of Student’s t-test and the Mann–
Whitney U-test, as appropriate. All tests of signiﬁcance were
two-tailed, and a p-value of <0.05 was considered to indicate
statistical signiﬁcance. Calculations were performed with SPSS
for Windows, version 21K (SPSS, Chicago, IL, USA).ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
684.e13 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIResultsPatient characteristics
During the study period, a total of 24 patients, consisting of 20
patientswith proven PM and fourwith probable PM,were enrolled
(Fig. 1). There were 234 patients, comprising 12 with proven IPA
and 222with probable IPA, during the study period (Fig. 1). Among
the 222 patients with probable IPA, 65 (29%) yielded positive
Aspergillus cultures from non-sterile specimens. Therefore, the 12
patients with proven IPA and the 65 patients with probable IPA
whose sputa or BAL ﬂuid yielded Aspergillus species were included
in the ﬁnal analysis. Of the remaining 157 patients with probable
IPAwho yielded negative Aspergillus cultures but positive GM assay
results, 19 patients selected at random were included in the ﬁnal
analysis. Thus, 96 patients, 12 (13%) with conﬁrmed IPA and 84
(87%) with probable IPA, were ﬁnally analysed.
The baseline characteristics, treatments and outcomes of all
of the patients are shown in Table 1. Almost half of the patients
with PM or IPA had haematological malignancies. The median
time between the ﬁrst clinical signs and the ﬁrst CT scan was
similar in the PM and IPA patients (PM, 6 days vs. IPA, 7 days; p
0.75). Interestingly, the serum GM assay gave positive results in
22% of the patients with PM and in 77% of those with IPA
(p < 0.001). The detailed clinical and mycological results of
patients with positive serum or BAL GM assay are shown in
Table S1.
CT features of PM and IPA
All but ﬁve patients underwent CT, based on the clinical sus-
picion. We compared the CT ﬁndings between the 24 patients
with PM and the 96 patients with IPA (Table 2). Typical clinical
cases and CT ﬁndings of the patients with IPA and PM are
shown in Figs S1 and S2, and Figs S3 and S4, respectively. TheFIG. 1. Schematic ﬂow chart of the study. IPA, invasive pulmonary aspergillo
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectRHS was more common in patients with PM than in those with
IPA (p 0.001) (Figs S3 and S4). Centrilobular nodules (<10 mm,
clustered) (p 0.04), peribronchial consolidations (p 0.01) and
smooth bronchial wall thickening (p 0.003)—typical airway-
invasive forms—were more common in patients with IPA
than in patients with PM (Fig S2). Solitary lesions were more
common in patients with PM than in patients with IPA (p 0.03).
In a subgroup analysis stratiﬁed by the 48 patients with neu-
tropenic status, mass-shaped consolidations (p 0.01) and the RHS
(p 0.005) were more common in neutropenic patients with PM
than in those with IPA (Table S2). Among the 72 non-
neutropenic patients, airway-invasive forms, including clusters
of centrilobular nodules (p 0.03), peribronchial consolidation (p
0.01), and bronchial wall thickening (p 0.005), were more com-
mon in patients with IPA than patients with PM, whereas the RHS
was more common in patients with PM (p < 0.001) (Table S3).
The RHS was more frequent in neutropenic patients with PM
(80% (4/5)) than in non-neutropenic patients with PM (47% (9/
19)), but the difference was not statistically signiﬁcant (p 0.19).
Evolution of CT ﬁndings in PM and IPA
The evolution of the CT ﬁndings in PM and IPA is shown in
Fig. 2. Between day 0 and day 5, nine patients with PM and 41
patients with IPA underwent CT scanning. The RHS was seen in
four of the former, and in three of 39 patients with IPA (p 0.02).
Almost half of the patients with IPA showed bronchial wall
thickening, as compared with none of the patients with PM.
Macronodules, mass-like consolidations and the RHS were
common features in both groups at this stage. From day 6 to
day 14, nine patients with PM and 36 patients with IPA un-
derwent CT scanning. The RHS was observed in seven of the
patients with PM and in one patient with IPA (p < 0.001). The
RHS only appeared within 5 days from symptom onset insis; PM, pulmonary mucormycosis.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
TABLE 1. Baseline clinical and mycological characteristics, treatments and outcomes of 24 patients with pulmonary mucormycosis
(PM) and 96 patients with invasive pulmonary aspergillosis (IPA)
Characteristic PM (n [ 24) IPA (n [ 96) p
Age (years), median (IQR) 51 (45–63) 52 (43–61) 0.88
Male gender, no. (%) 16 (67) 72 (75) 0.41
Underlying disease, no. (%)
Haematological malignancy 12 (50) 54 (56) 0.58
Solid organ transplant 4 (17) 36 (38) 0.053
Bone marrow transplant 5 (21) 22 (23) 0.83
Diabetes mellitus 11 (46) 29 (30) 0.15
Chronic kidney disease 4 (17) 15 (16) >0.99
Solid tumour 4 (17) 4 (4) 0.050
Underlying condition, no. (%)
Steroid usea 13 (54) 63 (66) 0.30
Immunosuppressant useb 8 (33) 53 (55) 0.06
Neutropenia (ANC < 500/m3) 5 (21) 43 (45) 0.03
Cytotoxic chemotherapy within 1 month 8 (33) 38 (40) 0.57
Patients with extrapulmonary location, no. (%) 7 (30) 5 (5) 0.002
Rhinocerebral 6 (25) 0 (0) <0.001
Gastrointestinal 3 (13) 0 (0) 0.007
Skin 0 (0) 3 (3) >0.99
Disseminated 5 (21)c 5 (5)d 0.03
Duration of neutropenia before diagnosis (days), median (IQR) 25 (16–130) 19 (10–39) 0.53
Median time from transplantation (days), median (IQR)e 176 (120–640) 104 (28–318) 0.11
Patients treated for >15 days with systemic antifungal agents within 6 months, no. (%) 6 (25) 39 (41) 0.16
Itraconazole 4 (17) 15 (16) >0.99
Polyene 0 (0) 12 (13) 0.12
Fluconazole 1 (4) 8 (8) 0.69
Echinocandin 1 (4) 5 (5) >0.99
Voriconazole 1 (4) 3 (3) >0.99
Posaconazole 1 (4) 1 (1) 0.36
Time between ﬁrst clinical signs and ﬁrst CT scan (days), median (IQR) 6 (3–11) 7 (3–14) 0.75
Diagnostic category of invasive fungal infection, no. (%) <0.001
Proven 20 (83)f 12 (13)g —
Probable 4 (17)h 84 (87) —
Positive culture in clinical specimen, no. (%) 7 (29) 73 (76) <0.001
Positive serum galactomannan assay, no. (%) 4/18 (22) 72/94 (77) <0.001
Positive BAL galactomannan assay, no. (%) 3/7 (43) 26/31 (84) 0.04
Antifungal therapy at diagnosis, no. (%)
Polyene 22 (92) 56 (58) 0.002
Voriconazole 0 (0) 32 (33) 0.001
Caspofungin 0 (0) 4 (4) 0.58
Outcome, no. (%)
30-day mortality 2 (8) 27 (28) 0.04
90-day mortality 8 (33) 41 (43) 0.40
180-day mortality 9 (38) 49 (51) 0.24
ANC, absolute neutrophil count; BAL, bronchoalveolar lavage; CT, computed tomography; IQR, interquartile range.
aCorticosteroid use is deﬁned as the use of corticosteroids at a mean minimum dose of 0.3 mg/kg/day of prednisolone equivalent for >3 weeks.
bTreatment with other recognized T-cell immunosuppressants, such as cyclosporine, tumour necrosis factor-α blockers, or speciﬁc monoclonal antibodies (such as alemtuzumab)
during the past 90 days.
cGastrointestinal tract involvement was found in two patients, a concurrent brain lesion was found in one patient, and multiple metastatic lesions (brain, thyroid, gastrointestinal
tract, and heart) were found in one patient.
dConcurrent skin lesions were found in two patients, multiple metastatic lesions (skin and brain) were found in one patient, and hepatic and hepatosplenic lesions were found in the
remaining two patients, respectively.
eThis analysis was limited to transplant recipients.
fThe 20 patients with proven PM showed histomorphology compatible with mucormycosis, and had positive results with the anti-Rhizopus arrhizus antibody but negative results with
the anti-Aspergillus antibody. Of the 20 patients with proven PM, one was positive for Absidia species from pulmonary tissue culture, and two were positive for Rhizopus species from
maxillary sinus and sputum culture, respectively.
gOf the 12 patients with proven IPA, 11 had available results of immunohistochemical staining with anti-Aspergillus antibody, and ten showed histomorphology compatible with
aspergillosis and had positive results with the anti-Aspergillus antibody but negative results with the anti-Rhizopus arrhizus antibody. The remaining two patients with proven IPA had
histomorphology compatible with aspergillosis, and yielded a positive Aspergillus culture from a sterile specimen.
hOf the four patients with probable PM, one was positive for Cunninghamella species from sputum culture, two were positive for Rhizopus species from sputum and BAL culture, and
one was positive for Mucor species from nasopharyngeal aspirate culture.
CMI Jung et al. Comparison of CT ﬁndings between PM and IPA 684.e14approximately half of the patients, but were observed within 14
days from symptom onset in ~80% of the patients (Fig. 2C).
Peribronchial consolidations and air-crescent signs were also
evident (p 0.02, respectively). After day 15, ﬁve of six patients
with PM showed mass-like consolidations (p 0.06).DiscussionThe low culture-positive rate of PM and the lack of biological
markers for PM make it difﬁcult to suspect PM early andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeprovide speciﬁc therapy for it; in addition, early clinical suspi-
cion of IPA is not sufﬁciently convincing to permit the admin-
istration of voriconazole therapy, as the GM assay has
insufﬁcient sensitivity to rule out IPA and not enough speciﬁcity
to rule in IPA. Here, we found that the RHS was speciﬁc for PM,
especially within 2 weeks from symptom onset, but it was not
sensitive enough to rule out PM, even early in the disease.
However we also found that certain types of airway-invasive
structure, such as centrilobular nodules, peribronchial consol-
idations, and bronchial wall thickening, were more common in
patients with IPA than in those with PM. Therefore, our ﬁndingsctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
TABLE 2. Comparison of computed tomography ﬁndings
between pulmonary mucormycosis (PM) and invasive
pulmonary aspergillosis (IPA)
PM (n [ 24),
no. (%)
IPA (n [ 96),
no. (%) p
Angioinvasive form
Macronodule
(1 cm in diameter)
10 (42) 46 (48) 0.58
Single 4 (17) 20 (21) 0.78
Multiple 6 (25) 26 (27) >0.99
Consolidation, mass-shaped 14 (58) 40 (42) 0.14
Single 11 (46) 26 (27) 0.08
Multiple 3 (13) 14 (15) >0.99
Consolidation, infarct-shaped 3 (13) 26 (27) 0.14
Single 0 (0) 13 (14) 0.07
Multiple 3 (13) 13 (14) >0.99
Halo sign 11 (40) 26 (27) 0.08
Airway-invasive form
Clusters of centrilobular
nodules (<1 cm)
7 (29) 50 (52) 0.04
Consolidation, peribronchial 5 (21) 47 (49) 0.01
Ground-glass opacity 10 (42) 52 (54) 0.27
Smooth bronchial wall thickening 1 (4) 33 (34) 0.003
Necrotizing pneumonia form
Air-crescent sign 3 (13) 6 (6) 0.38
Cavitary lesion 8 (33) 22 (23) 0.29
Internal low attenuation 10 (42) 24 (25) 0.11
Reverse halo sign 13 (54) 6 (6) <0.001
Typical reverse halo sign 5 (21) 3 (3) 0.01
Bird’s nest sign 8 (33) 3 (3) <0.001
Solitary lesion 9 (38) 16 (17) 0.03
Air bronchogram 10 (42) 37 (39) 0.78
Atelectasis 2 (8) 4 (4) 0.35
Hilar/mediastinal lesion 0 (0) 4 (4) 0.58
Pleural effusion 8 (33) 41 (43) 0.40
Pericardial effusion 1 (4) 12 (13) 0.46
684.e15 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIshould help clinicians to suspect and differentiate PM from IPA,
and, where appropriate, initiate Zygomycetes-active antifungal
treatment early.
Several retrospective studies have shown that the RHS is
present in PM. Vogl et al. reported that ﬁve of nine (56%) pa-
tients with PM had the BNS [13]. They ﬁrst described the BNS
in patients with PM, whose CT images were slightly different
from the typical RHS as seen from our perspective. Wahba
et al. observed the RHS in eight (22%) of 37 patients with
invasive mould infections, including seven with mucormycosis
and one with aspergillosis [14]. Recently, Legouge et al. re-
ported the RHS in 15 (94%) of 16 leukaemic patients with
mucormycosis during the ﬁrst week of the disease [6]. In
addition, the authors could not infer the diagnostic perfor-
mance of the RHS for the diagnosis of PM without comparing
the radiological ﬁndings for IPA with those for PM [6]. We
clearly showed that the RHS is speciﬁc for PM, but is not a very
sensitive marker for it. The reason for the differences in
sensitivity in the various studies is not clear. One possible
explanation could be that the CT scans were performed at
different stages of the disease. The previous study proposed
that the RHS appeared within 5 days of symptom onset, and
disappeared subsequently. However, we found that the RHS
only appeared within 5 days from symptom onset in one-Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectquarter of the patients, but was observed within 14 days
from symptom onset in ~80% of patients. However, only 38%
(9/24) of patients underwent a CT scan within 5 days from
symptom onset in this study, as compared with 100% (16/16) of
patients in the study of Legouge et al. [6]. In fact, the median
time from symptom onset to the ﬁrst CT scan in patients with
PM was 6 days in the present study, as compared with 1 day in
the study of Legouge et al. [6]. Therefore, further studies on
this are needed. Another possible explanation could be differ-
ences in host factors. For example, the previous study [6]
included 15 neutropenic patients among the 16 patients with
PM, whereas the current study included only ﬁve neutropenic
patients among the 24 patients with PM. It is therefore possible
that the RHS might be more frequent in the neutropenic state.
In fact, the RHS was seen in four of ﬁve neutropenic patients in
our study within 11 days from onset of symptoms. The
remaining patient only underwent a CT scan 19 days after
symptom onset. Taken together, these ﬁndings suggest that,
until further well-designed studies are available, it would be
better not to exclude PM when the RHS is absent, and that anti-
Zygomycetes agents should be administered promptly in the
presence of the RHS, as the RHS is uncommon in IPA.
As the pathophysiological mechanism of the RHS in fungal
pneumonia is not known, it is difﬁcult to explain why it is more
frequent in PM than in IPA. Okubo et al. showed that the centre
of the dense nodule in IPA consisted of an exudate in the
alveolar air space, whereas in PM the alveolar air space was not
ﬁlled with exudate [15]. The authors proposed that the
extensive penetration of Aspergillus into the lung was able to
induce plasma exudation, whereas Mucor penetrates through
the septal wall from the lumen of a capillary or the small
vasculature [15]. Thus, a difference in the intensity of pene-
tration and angio-invasiveness between Mucor and Aspergillus
could underlie the difference in the RHS between PM and IPA.
Further radiopathological correlation studies are needed.
In a previous study, we showed that airway-invasive forms
such as small-airway lesions and peribronchial consolidations
were frequent in non-neutropenic patients with IPA [4].
Therefore, the frequent ﬁnding of airway invasiveness in IPA
was not unexpected, because approximately half of the patients
with IPA did not have neutropenia. However, it is interesting
that a certain type of airway invasiveness was less frequent in
PM than in IPA. This could explain why Mucorales infections
generally occur earlier and are more angio-invasive than
Aspergillus infections [6]. This is also supported by our ﬁnding
that halo signs tend to be more frequent in PM than in IPA.
Therefore, we believe that a combination of the presence of the
RHS and an absence of airway invasiveness on CT images could
differentiate PM from IPA.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
FIG. 2. Comparison of the evolution of computed tomography ﬁndings between pulmonary mucormycosis and invasive pulmonary aspergillosis.
CMI Jung et al. Comparison of CT ﬁndings between PM and IPA 684.e16This study has several limitations. First, six (29%) of 21 pa-
tients with PM whose GM assay results were available yielded
positive serum or BAL GM assay results. Hence, some might
argue that the patients with PM who had positive GM assay
results could be misclassiﬁed. However, three of six patients
whose GM assays gave positive results also yielded Rhizopus
species and Mucor species from sterile culture or non-sterile
culture (Table S1). The possible explanations for positive GM
assay results in patients with proven PM could be the false-
positive GM assay results associated with use of antibiotics
such as piperacillin–tazobactam, blood products, or Plasma-
Lyte [16–18], the cross-reaction between the mucormycosis
antigen and GM [19], and the colonization of Aspergillus in the
damaged bronchi in patients with mucormycosis without overt
tissue invasion [20]. Therefore, cautious interpretation of
positive GM results is needed when a patient shows CT ﬁndings
compatible with fungal pneumonia without other mycologicalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeevidence. The second limitation was the difference in conﬁrmed
cases between PM and IPA. PM has no biomarker such as the
GM assay used for probable IPA, so the proportion of probable
PM cases was inevitably lower than that of probable IPA cases.
Therefore, many cases of PM with culture-negative cases were
not included in this study, and the patients who could tolerate
invasive work-up and survived until the invasive work-up for
PM were enrolled in this study. This type of selection bias could
be a partial explanation for the lower 30-day mortality in pa-
tients with PM than in those with IPA (Table 1). In this context,
the present study design would not be suitable for the com-
parison of outcome between PM and IPA. However, this bias
could not alter our main ﬁndings related to CT scans in this
study. It is worth noting that we clearly demonstrated that the
RHS was a speciﬁc sign for differentiating PM from IPA, by
showing that the RHS was observed in <5% of the patients with
IPA, despite the heterogeneity of the patients and thectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
684.e17 Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 CMIretrospective nature. Third, most of the patients with proven
mucormycosis and proven aspergillosis showed histomorphol-
ogy compatible with mucormycosis and aspergillosis, with
positive immunohistochemical stains, in the absence of positive
culture from sterile specimens. Some authors have therefore
questioned the diagnostic speciﬁcities of these commercially
available monoclonal antibodies for immunohistochemical
staining. When we evaluated the diagnostic performance for
mucormycosis and aspergillosis immunohistochemical staining
in patients with sterile culture-proven mucormycosis (n = 7)
and aspergillosis (n = 8) cases, the speciﬁcities for mucormy-
cosis and aspergillosis immunohistochemical staining were
100% and 100%, respectively (unpublished data). Therefore, we
believe that the commercially available monoclonal antibodies
for immunohistochemical staining are useful in distinguishing
between mucormycosis and aspergillosis, given that fungal cul-
ture has low sensitivity. Fourth, recent studies have shown that
the vascular occlusion sign is a sensitive and speciﬁc sign of
invasive mould pneumonia [21–23]. The fact that >60% (74/
120) of patients in our study had CT performed without
contrast enhancement could have affected the diagnostic ac-
curacy. However, the routine performance of CT angiography
in patients suspected of having invasive mould infection is a
controversial issue, owing to concerns about contrast-induced
acute renal failure. Further studies in this area are needed.
In conclusion, the RHS is a more frequent feature of PM than
of IPA; conversely, the airway-invasive form is a less common
feature of PM than of IPA. Together, these ﬁndings may help
physicians to pre-emptively initiate Zygomycetes-active anti-
fungal treatment.Transparency declarationThere are no potential conﬂicts of interest for any authors.AcknowledgementsThis work was supported by grants from the National Research
Foundation of Korea (Grant NRF-2013R1A1A1A05004354)
and the Asan Institute for Life Sciences (2015-0193).Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.cmi.2015.03.019.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectReferences[1] Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis
and aggressive surgery in the management of invasive pulmonary
aspergillosis in neutropenic patients. Clin Microbiol Infect
2001;7(Suppl. 2):54–61.
[2] Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-
based guidelines for empirical therapy of neutropenic fever in korea.
Korean J Intern Med 2011;26:220–52.
[3] Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C,
Lortholary O, et al. Imaging ﬁndings in acute invasive pulmonary
aspergillosis: clinical signiﬁcance of the halo sign. Clin Infect Dis
2007;44:373–9.
[4] Park SY, Lim C, Lee SO, Choi SH, Kim YS, Woo JH, et al. Computed
tomography ﬁndings in invasive pulmonary aspergillosis in non-
neutropenic transplant recipients and neutropenic patients, and their
prognostic value. J Infect 2011;63:447–56.
[5] Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP.
Predictors of pulmonary zygomycosis versus invasive pulmonary
aspergillosis in patients with cancer. Clin Infect Dis 2005;41:60–6.
[6] Legouge C, Caillot D, Chretien ML, Lafon I, Ferrant E, Audia S, et al.
The reversed halo sign: Pathognomonic pattern of pulmonary
mucormycosis in leukemic patients with neutropenia? Clin Infect Dis
2014;58:672–8.
[7] De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE,
Calandra T, et al. Revised deﬁnitions of invasive fungal disease from the
European Organization for Research and Treatment of Cancer/Inva-
sive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)
Consensus Group. Clin Infect Dis 2008;46:1813–21.
[8] Kim SH, Moon SM, Han SH, Chung JW, Moon SY, Lee MS, et al.
Epidemiology and clinical outcomes of invasive pulmonary aspergillosis:
a nationwide multicenter study in Korea. Infect Chemother 2012;44:
282–8.
[9] Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL,
Remy J. Fleischner society: glossary of terms for thoracic imaging.
Radiology 2008;246:697–722.
[10] Logan PM, Primack SL, Miller RR, Muller NL. Invasive aspergillosis of
the airways: radiographic, CT, and pathologic ﬁndings. Radiology
1994;193:383–8.
[11] Logan PM, Muller NL. High-resolution computed tomography and
pathologic ﬁndings in pulmonary aspergillosis: a pictorial essay. Can
Assoc Radiol J 1996;47:444–52.
[12] Walker CM, Mohammed TL, Chung JH. ‘Reversed halo sign’. J Thorac
Imaging 2011;26:W80.
[13] Vogl TJ, Hinrichs T, Jacobi V, Bohme A, Hoelzer D. [Computed
tomographic appearance of pulmonary mucormycosis]. Rofo
2000;172:604–8.
[14] Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed
halo sign in invasive pulmonary fungal infections. Clin Infect Dis
2008;46:1733–7.
[15] Okubo Y, Ishiwatari T, Izumi H, Sato F, Aki K, Sasai D, et al. Patho-
physiological implication of reversed CT halo sign in invasive pulmo-
nary mucormycosis: a rare case report. Diagn Pathol 2013;8:82.
[16] Martin-Rabadan P, Gijon P, Alonso Fernandez R, Ballesteros M,
Anguita J, Bouza E. False-positive aspergillus antigenemia due to blood
product conditioning ﬂuids. Clin Infect Dis 2012;55:e22–27.
[17] Petraitiene R, Petraitis V, Witt 3rd JR, Durkin MM, Bacher JD,
Wheat LJ, et al. Galactomannan antigenemia after infusion of
gluconate-containing plasma-lyte. J Clin Microbiol 2011;49:4330–2.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
CMI Jung et al. Comparison of CT ﬁndings between PM and IPA 684.e18[18] Park SY, Lee SO, Choi SH, Sung H, Kim MN, Choi CM, et al. Asper-
gillus galactomannan antigen assay in bronchoalveolar lavage ﬂuid for
diagnosis of invasive pulmonary aspergillosis. J Infect 2010;61:492–8.
[19] Borras R, Rosello P, Chilet M, Bravo D, de Lomas JG, Navarro D.
Positive result of the aspergillus galactomannan antigen assay using
bronchoalveolar lavage ﬂuid from a patient with an invasive infection
due to lichtheimia ramosa. J Clin Microbiol 2010;48:3035–6.
[20] Park SY, Lee SO, Choi SH, Jeong JY, Sung H, Kim MN, et al. Serum and
bronchoalveolar lavage ﬂuid galactomannan assays in patients with
pulmonary aspergilloma. Clin Infect Dis 2011;52:e149–152.
[21] Sonnet S, Buitrago-Tellez CH, Tamm M, Christen S, Steinbrich W.
Direct detection of angioinvasive pulmonary aspergillosis inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeimmunosuppressed patients: preliminary results with high-resolution
16-MDCT angiography. AJR Am J Roentgenol 2005;184:746–51.
[22] Stanzani M, Battista G, Sassi C, Lewis RE, Tolomelli G, Clissa C, et al.
Computed tomographic pulmonary angiography for diagnosis of
invasive mold diseases in patients with hematological malignancies. Clin
Infect Dis 2012;54:610–6.
[23] Stanzani M, Sassi C, Lewis RE, Tolomelli G, Bazzocchi A, Cavo M, et al.
High resolution computer tomography angiography improves the
radiographic diagnosis of invasive mold disease in patients with he-
matology malignancies. Clin Infect Dis 2015. http://dx.doi.org/10.1093/
cid/civ154.ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 684.e11–684.e18
